Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 384,001 shares of the life sciences company’s stock after selling 6,676 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Illumina were worth $53,468,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Acadian Asset Management LLC lifted its position in shares of Illumina by 312.5% during the 1st quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company’s stock valued at $702,000 after buying an additional 1,525 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Illumina by 3.1% during the first quarter. Dimensional Fund Advisors LP now owns 237,118 shares of the life sciences company’s stock worth $82,853,000 after purchasing an additional 7,114 shares in the last quarter. Dakota Wealth Management raised its stake in Illumina by 13.8% in the 1st quarter. Dakota Wealth Management now owns 826 shares of the life sciences company’s stock valued at $288,000 after purchasing an additional 100 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in Illumina by 16.9% in the 1st quarter. Sequoia Financial Advisors LLC now owns 803 shares of the life sciences company’s stock valued at $281,000 after purchasing an additional 116 shares in the last quarter. Finally, Baird Financial Group Inc. lifted its holdings in Illumina by 10.2% in the 1st quarter. Baird Financial Group Inc. now owns 48,943 shares of the life sciences company’s stock valued at $17,108,000 after purchasing an additional 4,548 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Illumina news, CEO Jacob Thaysen bought 7,330 shares of Illumina stock in a transaction that occurred on Thursday, February 22nd. The shares were purchased at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the transaction, the chief executive officer now owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.17% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ILMN. Barclays raised their price objective on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. HSBC lowered Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. TD Cowen lowered Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price objective on the stock. in a report on Thursday, January 4th. OTR Global restated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $253.00 target price on shares of Illumina in a research note on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $167.70.

Illumina Stock Down 1.4 %

Shares of NASDAQ:ILMN opened at $116.69 on Friday. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $232.23. The stock’s fifty day simple moving average is $133.78 and its 200-day simple moving average is $128.07. The company has a market capitalization of $18.58 billion, a P/E ratio of -15.90 and a beta of 1.19.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the business earned $0.14 earnings per share. The business’s revenue was up 3.6% on a year-over-year basis. As a group, equities research analysts forecast that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.